Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2012-01, Vol.26 (1), p.172-177
Hauptverfasser:	Gruber, F X, Ernst, T, Porkka, K, Engh, R A, Mikkola, I, Maier, J, Lange, T, Hochhaus, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Cancer Research Cancer therapies Chronic myeloid leukemia Cloning Critical Care Medicine Dasatinib Drug Resistance, Neoplasm Drug therapy Evolution & development Genetic aspects Health aspects Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Intensive Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Mutation Oncology Piperazines - therapeutic use Pyrimidines - therapeutic use Thiazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!